Skip to main content

05-06-2024 | Rectal Cancer | News

ASCO 2024

Complete responses with dostarlimab in mismatch repair deficient locally advanced rectal carcinoma appear durable PD-1 blockade with dostarlimab for 6 months produces a durable relapse-free response in locally advanced rectal carcinoma with mismatch repair deficiencies. Of 42 patients treated, 100% achieved a clinical complete response and these appear to be durable, a US phase 2 study shows.

Related topics